Why “we’re safe” is the most dangerous assumption in medical benefit commercialization.
Bill Roth
Advertisement
Bill Roth, SVP of Consulting and Advisory, IntegriChain.
Articles by Bill Roth
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
2
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
3
ANI Pharmaceuticals to Acquire Egetis Therapeutics, Egetis Sells Priority Review Voucher for $190 Million
4
Roundup: Boehringer Ingelheim Licenses Six Oncology Programs From Sino Biopharmaceutical, Nxera Licenses EP4 Agonist to AbbVie
5